Conclusions
To conclude, our results demonstrate that treatment with sofosbuvir/daclatasvir is highly effective in liver fibrosis regression in HCV-infected cirrhotic patients. Furthermore, HCV eradication in patients with higher levels of hepatic steatosis led to improvement in steatosis (CAP value). Future studies with larger sample size, longer follow-up period, and more precise methods for liver histology assessment are required to strengthen the current findings, overcome limitations, and elucidate all affective factors contributing to liver fibrosis regression in chronic HCV patients receiving DAAs therapy.